• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Friday, February 3, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Cambridge

Zacks: Analysts Expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Will Post Quarterly Sales Of $410,000.00

by Duong
February 27, 2022
in Cambridge
zacks:-analysts-expect-infinity-pharmaceuticals,-inc-(nasdaq:infi)-will-post-quarterly-sales-of-$410,000.00
Share on FacebookShare on Twitter

Infinity Pharmaceuticals logoEquities analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI – Get Rating) to report sales of $410,000.00 for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from $200,000.00 to $550,000.00. Infinity Pharmaceuticals reported sales of $440,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 6.8%. The firm is expected to report its next quarterly earnings results on Tuesday, March 15th.

On average, analysts expect that Infinity Pharmaceuticals will report full-year sales of $1.68 million for the current fiscal year, with estimates ranging from $1.00 million to $1.96 million. For the next year, analysts anticipate that the business will post sales of $1.65 million, with estimates ranging from $800,000.00 to $2.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Infinity Pharmaceuticals.

A number of research analysts have commented on the stock. Zacks Investment Research downgraded shares of Infinity Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Tuesday, January 11th. StockNews.com raised shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 15th. B. Riley cut their target price on shares of Infinity Pharmaceuticals from $7.00 to $5.00 in a research report on Monday, January 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Infinity Pharmaceuticals in a research report on Monday, December 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. According to MarketBeat, Infinity Pharmaceuticals presently has an average rating of “Buy” and an average target price of $8.11.

(Ad)

Don’t be fooled by other guides showing off their once-in-a-lifetime or horribly out of date trade examples.

“Options Basics” will give you real world and real time trade examples to help you grow your account while minimizing risk!

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Infinity Pharmaceuticals by 11.4% in the 4th quarter. BlackRock Inc. now owns 6,667,503 shares of the biotechnology company’s stock worth $15,001,000 after purchasing an additional 684,014 shares in the last quarter. Vanguard Group Inc. boosted its stake in Infinity Pharmaceuticals by 23.7% in the 2nd quarter. Vanguard Group Inc. now owns 4,382,805 shares of the biotechnology company’s stock worth $13,105,000 after purchasing an additional 838,751 shares in the last quarter. Polar Capital Holdings Plc acquired a new stake in Infinity Pharmaceuticals in the 3rd quarter worth approximately $8,550,000. State Street Corp boosted its stake in Infinity Pharmaceuticals by 5.4% in the 4th quarter. State Street Corp now owns 1,798,973 shares of the biotechnology company’s stock worth $4,048,000 after purchasing an additional 91,752 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Infinity Pharmaceuticals by 22.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,734,032 shares of the biotechnology company’s stock worth $5,930,000 after purchasing an additional 319,114 shares in the last quarter. Institutional investors own 53.07% of the company’s stock.

NASDAQ INFI opened at $1.13 on Friday. The company has a market capitalization of $100.58 million, a price-to-earnings ratio of -1.98 and a beta of 2.11. The company’s 50-day simple moving average is $1.54 and its two-hundred day simple moving average is $2.41. Infinity Pharmaceuticals has a one year low of $0.97 and a one year high of $3.89.

About Infinity Pharmaceuticals (Get Rating)

Infinity Pharmaceuticals, Inc operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Read More

  • Get a free copy of the StockNews.com research report on Infinity Pharmaceuticals (INFI)
  • 3 Glass Stocks that Could Sharpen Your Portfolio
  • The Top 3 Stocks to Buy in March
  • MarketBeat: Week in Review 2/21 – 2/25
  • Volatility Spikes On Russian Aggression In Ukraine 
  • Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Infinity Pharmaceuticals right now?

Before you consider Infinity Pharmaceuticals, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Infinity Pharmaceuticals wasn’t on the list.

While Infinity Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Read More Here

Related Posts

head-to-head-survey:-voyager-therapeutics-(nasdaq:vygr)-&-surface-oncology-(nasdaq:surf)

Head-To-Head Survey: Voyager Therapeutics (NASDAQ:VYGR) & Surface Oncology (NASDAQ:SURF)

by Duong
April 14, 2022
0

Posted by admin on Apr 14th, 2022 Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk...

energy-workshop-–-announcements-–-e-flux

Energy Workshop – Announcements – E-Flux

by Duong
April 13, 2022
0

The first edition of the Norman Foster Foundation’s Energy Workshop will take place from April 25–29, 2022 with the support of GS Energy. “With energy, we stand on the shoulders of giants with our heads in the clouds,” states the workshop’s Mentor, Luke Olsen. As he puts it, “we need to...

men’s-and-women’s-tennis-complete-successful-weekend-with-wins-over-columbia,-cornell-|-sports-|-the-harvard-crimson

Men’s And Women’s Tennis Complete Successful Weekend With Wins Over Columbia, Cornell | Sports | The Harvard Crimson

by NewsReporter
April 12, 2022
0

“One thing that our team has really come a long way in this semester is with our confidence and belief in ourselves,” said first-year Holly Fischer. “So I think that even though we were down, everyone who was playing was fighting so hard and really leaving everything out on the...

artist-pritika-chowdhry’s-‘anti-memorials’-illustrate-what-is-excluded-from-collective-memories-of-partition

Artist Pritika Chowdhry’s ‘anti-Memorials’ Illustrate What Is Excluded From Collective Memories Of Partition

by Duong
April 11, 2022
0

The Jallianwala Bagh Massacre is one of the most significant events in the history of the sub-continent. Many people, including women and children, lost their lives on April 13, 1919, the day of Baisakhi when General Reginald Edward Dy ordered soldiers to open fire on the gathering — camping in...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT